多西他赛联合顺铂或卡铂治疗晚期非小细胞肺癌的临床观察  

Clinical observation of docetaxel combined with cisplatin or carboplatin in the treatment of advanced non-small cell lung cancer

作　　者：徐建芳[1] 刘驯炎[1] 

机构地区：[1]广东省汕头市中心医院肿瘤内科,广东汕头515031

出　　处：《现代肿瘤医学》2009年第7期1269-1271,共3页Journal of Modern Oncology

摘　　要：目的:观察多西他赛联合顺铂或卡铂治疗晚期非小细胞肺癌的临床疗效及不良反应。方法:共有56例经病理学和/或细胞学证实的晚期非小细胞肺癌患者入组,多西他赛联合顺铂治疗37例,多西他赛联合卡铂治疗19例,多西他赛75mg/m2,静脉滴注1小时,第1天,顺铂40mg/m2,静脉滴注,第2-3天,或卡铂ACU=5(300-400mg/m2),第2天或第2-3天分次给予,28天为1个周期,化疗2个周期后按WHO标准评价疗效及不良反应。结果:CR1例,PR26例,SD20例,PD9例,有效率48.2%(27/56),不良反应主要为骨髓抑制、恶心、呕吐和脱发。结论:多西他赛联合顺铂或卡铂治疗晚期非小细胞肺癌疗效确切,不良反应能耐受,值得进一步临床研究。Objective：To observe the efficacy and toxicities of docetaxel combined with cisplatin or carboplatin in the treatment of patients with advanced nor-small cell lung cancer（NSCLC）. Methods： Fifty -six patients with advanced NSCLC confirmed pathologically and/or cytologically were enrolled into the study, thirty - seven patients received docetaxel plus eisplatin, nineteen patients received docetaxel plus carboplatin ,docetaxel 75mg/m^2, 1 -hour intravenous infusion, d1, eisplatin 40mg/m^2, intravenous infusion, d2- 3, or earboplatin ACU = 5 （ 300 - 400mg/m^2 ）, d2 or d2 -3 dividually, the chemotherapy was repeated every 28 days, the efficacy and toxicities were assessed after two cycles. Results：There were 1 CR ,26 PR,20 SD and 9 PD among all patients after treatment, the overall response rate was 48.2% （27/56）. The major toxieities included myelosuppression, nausea, vomiting and alopecia. Conclusion ： The combined chemotherapy of docetaxel with cisplatin or carboplatin is effective in the treatment of patients with advanced nor- small cell lung cancer and toxicities are tolerable, further clinical investigation should be warranted.

关 键 词：非小细胞肺癌 化疗 多西他赛 顺铂 卡铂 

分 类 号：R734.2[医药卫生—肿瘤]